• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Real-World Evidence of Significant and Sustained Outcomes Following 60-Day Peripheral Nerve Stimulation Treatment for Chronic Pain

June 1, 2022

Real-world evidence (RWE), derived from analysis of data from the routine use of a treatment or therapy in general clinical practice, has an important role in providing insight into treatment effectiveness outside of the environment of clinical research. Increased recognition of the importance of RWE has led to recent calls in the neuromodulation field to increase the collection and sharing of RWE to improve clinical practice and clinical guidelines. The SPRINT PNS® System, which delivers short-term peripheral nerve stimulation percutaneously for up to 60 days, has been studied extensively in clinical trials, demonstrating significant and sustained chronic pain relief in a majority of patients across multiple pain indications such as chronic shoulder pain, low back pain, post-operative pain and post-amputation pain. However, outside of small retrospective case series and individual case reports, few real-world data have been published regarding the use of 60-day PNS.

Dr. Matthew Pingree and colleagues – Drs. Mark Hurdle, David Spinner and Ali Valimahomed along with members of SPR Therapeutics’ R&D team, Nathan Crosby, PhD and Joseph Boggs, PhD – recently published a manuscript in Pain Management representing the largest set of real-world data to date regarding the effectiveness and long-term impact of 60-day PNS treatment. The team of investigators sought to determine if 60-day PNS treatment could provide long-term relief in a real-world setting based on the results of a cross-sectional follow-up survey of patients who previously underwent treatment with the SPRINT PNS System.

The survey was distributed to patients from a national real-world database of SPRINT PNS users who had previously agreed to opt into a follow-up survey.  It used validated pain outcomes to assess patients’ current pain levels, changes in quality of life, and changes in analgesic medication usage compared to before they started the SPRINT treatment. Analysis focused on the 252 survey respondents who were at least three months from the time they started PNS treatment, and follow-up durations ranged up to 30 months.

Dr. Pingree and colleagues found that 73% of the survey respondents who were at least three months from the time they started PNS treatment (185/252) had been treatment responders at the end of the 60-day treatment, with at least 50% pain relief and/or clinically significant improvement in their quality of life. At the time of survey completion, 61% (112/185) of those treatment responders reported sustained improvements in pain and/or quality of life, including some of those who were more than two years post-treatment (Figure A). This RWE corroborates previously published clinical studies with follow-up durations of up to 12 months, which have consistently found that a majority of subjects reported substantial pain relief (≥50%) and resulting improvements in function. The RWE also supports that many patients can achieve sustained long-term improvements even outside the more rigorous environment of a prospective clinical trial and indicates that the outcomes of previously published prospective studies can be replicated in broader clinical practice.

Additionally, 35% (44/126) of those that reported using opioids before beginning the 60-day PNS treatment and 32% (47/147) of patients reporting anti-convulsant (e.g., gabapentin, pregabalin) usage before beginning treatment reported reducing or ceasing usage as of the time of survey completion (Figure B). Reducing analgesic medication usage, especially opioid analgesics, has become a priority of physicians in recent years in response to the opioid epidemic. Reducing chronic analgesic usage can also help reduce the substantial socioeconomic costs and burden on the healthcare system of opioid abuse and misuse. As a nonpharmacological intervention that does not require permanent implantation and may help reduce reliance on opioid and non-opioid analgesics, 60-day PNS can be an important and minimally invasive part of the treatment options available to physicians and patients for pain relief.

While the survey did not contain questions about adverse events as the patients had already completed treatment, data collected by SPR show that the most commonly reported adverse event has been adhesive-related skin irritation.  Serious adverse events have occurred in less than 1% of patients.

This study represents the largest body of real-world evidence published to-date supporting the effectiveness of 60-day PNS treatment, including significant and sustained pain relief and improvements in quality of life for a large proportion of respondents. These real-world data are consistent with the findings of published prospective studies that have demonstrated significant and sustained improvements following short-term PNS and support the benefits of 60-day PNS for the treatment of a wide range of pain conditions in broader clinical practice.

Real-World Evidence of Significant and Sustained Outcomes Graphs

Figure A) Proportion of patients who were responders at the end of treatment (EOT Responders) and maintained at least 50% pain relief and/or improvement in quality of life at the time of survey completion, grouped by months from the start of treatment. Figure B) Proportion of patients who were using opioid medications (n=126) or anti-convulsant medications (n=147) before beginning treatment who reported cessation or reduction of opioid or anti-convulsant medications at the time of survey completion.


The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. 

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.  

Important safety & risk information: https://bit.ly/2FU92NH


Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: 60-day percutaneous PNS, Chronic Pain, PNS, SPRINT PNS, SPRINT PNS System
Previous Post:10,000+ ImplantsSPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-Altering Pain 
Next Post:SPR Therapeutics Named a Top WorkplaceOur People Make All the Difference

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo